348 related articles for article (PubMed ID: 8181328)
1. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group.
Chest; 1994 May; 105(5):1411-9. PubMed ID: 8181328
[TBL] [Abstract][Full Text] [Related]
2. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease.
Levin DC; Little KS; Laughlin KR; Galbraith JM; Gustman PM; Murphy D; Kram JA; Hardie G; Reuter C; Ostransky D; McFarland K; Petty TL; Silvers W; Rennard SI; Mueller M; Repsher LH; Zuwallack RL; Vale R
Am J Med; 1996 Jan; 100(1A):40S-48S. PubMed ID: 8610716
[TBL] [Abstract][Full Text] [Related]
3. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group.
Gross N; Tashkin D; Miller R; Oren J; Coleman W; Linberg S
Respiration; 1998; 65(5):354-62. PubMed ID: 9782217
[TBL] [Abstract][Full Text] [Related]
4. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD.
Karpel JP; Kotch A; Zinny M; Pesin J; Alleyne W
Chest; 1994 Apr; 105(4):1089-94. PubMed ID: 8162730
[TBL] [Abstract][Full Text] [Related]
5. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base.
Campbell S
Arch Intern Med; 1999 Jan; 159(2):156-60. PubMed ID: 9927098
[TBL] [Abstract][Full Text] [Related]
6. Is oral theophylline effective in combination with both inhaled anticholinergic agent and inhaled beta 2-agonist in the treatment of stable COPD?
Nishimura K; Koyama H; Ikeda A; Izumi T
Chest; 1993 Jul; 104(1):179-84. PubMed ID: 8325065
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.
Friedman M; Serby CW; Menjoge SS; Wilson JD; Hilleman DE; Witek TJ
Chest; 1999 Mar; 115(3):635-41. PubMed ID: 10084468
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
Donohue JF; Wise R; Busse WW; Garfinkel S; Zubek VB; Ghafouri M; Manuel RC; Schlenker-Herceg R; Bleecker ER
BMC Pulm Med; 2016 Apr; 16(1):65. PubMed ID: 27130202
[TBL] [Abstract][Full Text] [Related]
10. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease.
Colice GL
Am J Med; 1996 Jan; 100(1A):11S-18S. PubMed ID: 8610712
[TBL] [Abstract][Full Text] [Related]
11. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD.
Nishimura K; Koyama H; Ikeda A; Sugiura N; Kawakatsu K; Izumi T
Chest; 1995 Mar; 107(3):718-23. PubMed ID: 7874943
[TBL] [Abstract][Full Text] [Related]
12. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
13. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study.
D'Urzo AD; De Salvo MC; Ramirez-Rivera A; Almeida J; Sichletidis L; Rapatz G; Kottakis J;
Chest; 2001 May; 119(5):1347-56. PubMed ID: 11348938
[TBL] [Abstract][Full Text] [Related]
14. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
[TBL] [Abstract][Full Text] [Related]
16. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.
Dorinsky PM; Reisner C; Ferguson GT; Menjoge SS; Serby CW; Witek TJ
Chest; 1999 Apr; 115(4):966-71. PubMed ID: 10208193
[TBL] [Abstract][Full Text] [Related]
17. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group.
Chest; 1997 Dec; 112(6):1514-21. PubMed ID: 9404747
[TBL] [Abstract][Full Text] [Related]
18. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department.
Rodrigo GJ; Rodrigo C
Am J Respir Crit Care Med; 2000 Jun; 161(6):1862-8. PubMed ID: 10852758
[TBL] [Abstract][Full Text] [Related]
19. Is an anticholinergic agent superior to a beta 2-agonist in improving dyspnea and exercise limitation in COPD?
Blosser SA; Maxwell SL; Reeves-Hoche MK; Localio AR; Zwillich CW
Chest; 1995 Sep; 108(3):730-5. PubMed ID: 7656624
[TBL] [Abstract][Full Text] [Related]
20. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease.
Ikeda A; Nishimura K; Koyama H; Tsukino M; Mishima M; Izumi T
Thorax; 1996 Jan; 51(1):48-53. PubMed ID: 8658369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
